扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较
Comparison of the Therapeutic Effect of FuzhengHuayu Tablet and Polyene Phosphatidylcholine on Nonalcoholic Fatty Liver
摘要: 目的:探讨扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效。方法:本次研究中所纳入的研究对象为我院医治的120例非酒精性脂肪肝患者,选取的时间段为2019年1月至2019年12月,按不同的治疗方式分为对照组(n = 60)与观察组(n = 60),对照组采用多烯磷脂酰胆碱治疗,观察组采用扶正化瘀片治疗。观察两组患者肝功能变化情况。结果:两组患者治疗前ALT、AST、TBil无明显差异(P > 0.05),治疗3周、治疗12周后观察组患者GGT指标均明显低于对照组患者(P < 0.05)。两组治疗前后比较BMI值、W/H值,统计学差异明显(P > 0.05),但治疗后对照组实验组比较无统计学差异(P < 0.05)。实验组、对照组治疗前B型超声积明显高于治疗后(P > 0.05);两组治疗后比较无明显差异(P < 0.05)。结论:采用扶正化瘀片治疗非酒精性脂肪肝,能明显改善患者的肝功能指标及肝脏组织学评分,疗效确切,值得应用。
Abstract: Objective: To explore the therapeutic effect of FuzhengHuayu tablet and polyene phosphatidylcholine on nonalcoholic fatty liver. Methods: 120 cases of nonalcoholic fatty liver treated in our hospital were included in this study. The selected period was from January 2019 to December 2019. According to different treatment methods, they were divided into the control group (n = 60) and the observation group (n = 60). The control group was treated with polyene phosphatidylcholine, and the observation group was treated with FuzhengHuayu tablet. The changes of liver function in the two groups were observed. Results: There was no significant difference in alt, AST and TBIL between the two groups before treatment (P > 0.05). GGT indexes of observation group were significantly lower than those of control group after 3 weeks and 12 weeks of treatment (P < 0.05). The BMI and W/H of the two groups were compared before and after treatment, the difference was statistically significant (P > 0.05), but there was no statistical difference between the two groups (P < 0.05). The B-mode ultrasound volume of the experimental group and the control group before treatment was significantly higher than that after treatment (P > 0.05); there was no significant difference between the two groups after treatment (P < 0.05). Conclusion: Using FuzhengHuayu tablet to treat nonalcoholic fatty liver can obviously improve the liver function index and liver histology score of patients, the curative effect is accurate, and it is worth applying.
文章引用:莫伟斌, 欧阳婉爱. 扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较[J]. 临床医学进展, 2021, 11(2): 439-443. https://doi.org/10.12677/ACM.2021.112062

参考文献

[1] 肖敏. 多烯磷脂酰胆碱联合水飞蓟宾治疗非酒精性脂肪肝患者的临床效果分析[J]. 医学理论与实践, 2018, 31(6): 833-834.
[2] 郭振营. 胆宁片联合多烯磷脂酰胆碱治疗非酒精性脂肪肝疗效观察[J]. 实用中西医结合临床, 2018, 18(4): 72-74.
[3] 史文龙. 多烯磷脂酰胆碱联合二甲双胍对非酒精性脂肪肝患者血清IL-17及TGF-β水平的影响观察[J]. 现代诊断与治疗, 2018, 29(21): 3427-3428.
[4] Liu, R., He, J., Liu, X.F., et al. (2018) Microarray Analysis of Polyene Phosphatidylcholine Intervention on Rat Nonalcoholic Fatty Liver Cell Model. China Tissue Engineering Research, 22, 99-105.
[5] 安慎富, 杨娅娟, 燕飞. 中西医结合治疗非酒精性脂肪肝疗效观察[J]. 山西中医, 2019, 35(1): 25-26.
[6] 李滨, 张佳圆, 王凤永, 等. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响[J]. 解放军医药杂志, 2018, 30(10): 93-96.
[7] 朱桂丽. 多烯磷脂酰胆碱胶囊联合非诺贝特片治疗32例老年中重度非酒精性脂肪肝的临床研究[J]. 北方药学, 2019, 16(5): 95-96.
[8] 卢火明. 异甘草酸镁与多烯磷脂酰胆碱治疗脂肪肝对ALT、AST指标变化以及临床疗效的影响[J]. 中国实用医药, 2019, 14(3): 12-14.
[9] Gao, J.L. (2019) Effect of Huazhuoquyu Formula Combined with Polyene Phosphatidylcholine on Liver Function and Blood Lipid Level in Patients with Nonalcoholic Fatty Liver. Chinese Folk Therapy, 27, 68-70.
[10] 李晓永, 张国顺. 扶正化瘀胶囊联合异甘草酸镁治疗失代偿期肝硬化患者的临床效果[J]. 中国医药导报, 2019, 16(11): 144-147.
[11] Lu, J. (2019) Effect of Polyene Phosphatidylcholine Capsule Combined with Reduced Glutathione in the Treatment of Nonalcoholic Fatty Liver. Chinese Medical Journal of Minkang, 31, 28-30.
[12] 李玉贤, 张汾燕, 崔振. 熊去氧胆酸联合扶正化瘀胶囊治疗HBeAg阳性高病毒载量乙肝肝硬化患者的疗效及对肝纤维化和炎性因子的影响[J]. 现代中西医结合杂志, 2018, 27(18): 2016-2019.
[13] 霍苗苗, 程变巧, 林伟国. 扶正化瘀方对非酒精性脂肪性肝病大鼠肝纤维化及ACE-AngII-AT1R轴的影响[J]. 解放军医学杂志, 2018, 43(2): 114-119.
[14] Wu, J., Huang, X.T. and Peng, Y.Z. (2019) Clinical Observation of JieyuShugan Decoction Combined with Polyene Phosphatidylcholine Capsule in the Treatment of Nonalcoholic Fatty Liver. Journal of Practical Chinese Medicine, 35, 826-827.
[15] Li, J.J. (2019) Clinical Study on the Treatment of 44 Elderly Patients with Moderate and Severe Nonalcoholic Fatty Liver by Polyene Phosphatidylcholine Combined with Fenofibrate Tablets. Modern Medical Imaging, 28, 220-221.